Drug Interaction Potentiation Clinical Trial
Official title:
A Pilot Prospective, Randomized Controlled Trial Assessing the Clinical Impact of Integrated Pharmacogenetic Testing on Selected OASIS Metrics, Re-hospitalizations and Emergency Department Visits
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing. In this open-label trial, a pharmacist will make medication therapy recommendations using YouScript® Personalized Prescribing System for patients who receive genetic testing and standard drug information resources per usual for patients who do not undergo pharmacogenetic testing.
Both groups will be followed for 60 days. The number of re-hospitalizations and emergency department (ED) visits will be recorded as well as time to first re-hospitalization and time to first ED visit. Select Outcome and Assessment Information Set (OASIS) metrics (e.g. M1034, M1242, M1710, M1720, M1745, M2110) and Patient Health Questionnaire (PHQ)-2 will be evaluated and documented at time of admission to home health, at 30 days, and at 60 days for improvement in overall status, pain, confusion, anxiety, depression, disruptive behavior, and the need for assistance with activities of daily living (ADLs) and instrumental activities of daily living (IADLs). The number of falls will be collected as well as the proportion of YouScript® recommendations accepted by study pharmacist and passed on to clinicians and the proportion of recommendations accepted by clinicians. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03789032 -
Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat
|
Phase 1 | |
Completed |
NCT03706222 -
Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan
|
||
Completed |
NCT02191358 -
YouScript IMPACT Registry
|
N/A | |
Completed |
NCT02485028 -
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg
|
Phase 1 | |
Completed |
NCT01896557 -
Ranitidin Versus Omeprazole in Patients Taking Clopidogrel
|
Phase 4 | |
Completed |
NCT03011463 -
Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1
|
Phase 1 | |
Completed |
NCT02485041 -
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg
|
Phase 1 | |
Completed |
NCT01477424 -
A Drug-Drug Interaction Study of Warfarin and PA21
|
Phase 1 | |
Completed |
NCT01477411 -
A Drug-Drug Interaction Study of Digoxin and PA21
|
Phase 1 | |
Completed |
NCT05558150 -
Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac
|
Phase 1 | |
Completed |
NCT03493698 -
A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03126578 -
Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam
|
Phase 1 | |
Completed |
NCT01369186 -
Drug Drug Interactions of Aspirin and P2Y12-inhibitors
|
Phase 4 | |
Completed |
NCT01324752 -
A Drug-Drug Interaction Study of Losartan and PA21
|
Phase 1 | |
Completed |
NCT02500667 -
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT03801733 -
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
|
Phase 1 | |
Completed |
NCT03801746 -
Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
|
Phase 1 | |
Completed |
NCT03801759 -
Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
|
Phase 1 | |
Completed |
NCT01736371 -
Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion.
|
N/A | |
Completed |
NCT05237297 -
Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole
|
Phase 1 |